East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Vigabatrin Tablets USP, 500 mg.  Aurobindo Pharma’s Vigabatrin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), SABRIL® tablets, manufactured by Lundbeck Pharmaceuticals LLC. 

Vigabatrin Tablets are indicated for:

• Adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures.